Clinical Trial Detail

NCT ID NCT03719898
Title Brigatinib in Relapsed or Refractory ALK-Positive Anaplastic Large Cell Lymphoma
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Fox Chase Cancer Center
Indications

anaplastic large cell lymphoma

Therapies

Brigatinib

Age Groups: adult senior

Additional content available in CKB BOOST